Program - Society of Toxicology

More documents

Recommendations

Info

50 th Anniversary Annual Meeting and ToxExpo Program Description (Continued) MONday Abstract # Abstract # #848 2:36 MINIMUM MATERIAL CHARACTERIZATIONS FOR NANOTOXICOLOGY STUDIES: A NECESSITY OR A NUISANCE? N. J. Walker. National Toxicology Program, NIEHS, Research Triangle Park, NC. #849 3:02 THE SELECTION AND CHARACTERIZATION OF NANOMATERIALS FOR DEVELOPING TOXICOLOGICAL QSARS. S. Oldenburg 1 , A. Neigh 1 , O. Nguyen 1 and S. Ali 2 . 1 nanoComposix, San Diego, CA and 2 NCTR /U.S. FDA, Jefferson, AR. #850 3:28 DOSIMETRIC CONSIDERATIONS FOR EXPLORING THE CYTOTOXICITY OF SILICA NANOPARTICLES IN VITRO. D. F. Lison 1 , V. Rabolli 1 and L. Thomassen 2 . 1 Louvain Centre for Toxicology and Applied Pharmacology, Brussels, Belgium and 2 Centrum voor Oppervlaktechemie en Katalyse, Katholieke Universiteit Leuven, Leuven, Belgium. #851 3:54 ENABLING PREDICTION AND EXTRAPOLATION: A NEW PARADIGM FOR NANOMATERIAL DOSIMETRY IN VITRO. J. G. Teeguarden 1 , P. M. Hinderliter 2 , G. Orr 3 , K. R. Minard 2 , B. D. Thrall 2 and J. G. Pounds 2 . 1 Biological Monitoring and Modeling, Pacific Northwest National Laboratory, Richland, WA, 2 Biological Sciences, Pacific Northwest National Laboratory, Richland, WA and 3 Environmental and Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA. 4:20 PANEL DISCUSSION/Q&A. Monday Afternoon, March 7 2:00 PM to 4:45 PM Room 144 Workshop Session: Understanding Structural and Physical Chemical Drivers of Drug Toxicity: Utility and Translatable Value Chairperson(s): Dylan Hartley, Genentech, South San Francisco, CA, and Manfred Kansy, F. Hoffman-LaRoche, Basel, Switzerland. Sponsor: Drug Discovery Toxicology Specialty Section Endorsed by: Biological Modeling Specialty Section In Vitro and Alternative Methods Specialty Section Given the demands on drug discovery teams to produce effective, specific, and safe new molecules, toxicologists are now finding themselves with new responsibilities in the drug discovery setting as part of lead optimization teams. To be effective members of these teams, toxicologists are now required to gain awareness and experience in recognizing potential structural and physicochemical properties of compounds that often lend to certain off-target toxicities, such as off-target receptor activities, QT-interval prolongation, phospholipidosis, enzyme induction, liver injury, and genotoxicity. The understanding of structural attributes of compounds that may drive specific liabilities will enhance the toxicologist’s contributions by enabling active collaboration with chemists to inform synthesis of new molecules to gain a safety advantage over previous molecules. To this end, in vitro assays (e.g., hERG channel inhibition, pharmacology ligand binding panels, enzyme induction, and transporter inhibition), coupled with specific mathematical or statistical models, and pharmacophore models (e.g., hERG channel and PXR activation) can be effective at instructing chemical modifications to attenuate the potential for activity against specific toxicological endpoints a priori. Furthermore, new in silico approaches in chemoinformatics are proving useful for predicting off-target polypharmacology by mapping potential drug-target interactions through ligand-based similarities. Similarly, mapping adverse drug reactions to chemical space may hold promise for predicting specific features of compounds that lead to adverse drug reactions in humans. Finally, detailed assessments of pharmacokinetic or physical chemical drivers of tissue accumulation are improving our understanding of in vitro—in vivo correlations. Overall these approaches demonstrate the importance and utility of understanding structural motifs and physicochemical properties of compounds that lead to off-target activity. #852 2:00 UNDERSTANDING STRUCTURAL AND PHYSICAL CHEMICAL DRIVERS OF DRUG TOXICITY: UTILITY AND TRANSLATABLE VALUE. D. P. Hartley 1 and M. Kansy 2 . 1 Genentech, South San Francisco, CA and 2 F. Hoffmann-LaRoche AG, Basel, Switzerland. 2:00 INTRODUCTION. Dylan Hartley #853 2:05 CLINICAL TRANSLATIONAL VALUE OF PHARMACOLOGICAL PROMISCUITY OBSERVED IN IN VITRO SAFETY PROFILING. L. A. Urban 1 , S. Whitebread 1 , J. Hamon 2 , K. Azzaoui 2 and D. Mikhailov 1 . 1 Center for Proteomic Chemistry, NIBR, Cambridge, MA and 2 Center for Proteomic Chemistry, NIBR, Basel, Switzerland. #854 2:37 PREDICTING DRUG OFF-TARGETS UNDERLYING ADVERSE EVENTS. M. Keiser 1,2 and B. Shoichet 2 . 1 SeaChange Pharmaceuticals, Inc., San Francisco, CA and 2 Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA. Sponsor: D. Hartley. #855 3:09 EARLY SAFETY PROFILING IN DRUG DISCOVERY: HOW STRUCTURAL AND PHYSICOCHEMICAL COMPOUND CHARACTERISTICS INFLUENCE THE SAFETY PROFILE OF DRUG CANDIDATES. M. Kansy and H. Fischer. Nonclinical Safety, F. Hoffmann-La Roche Ltd., Basel, Switzerland. #856 3:41 PHARMACOKINETIC DRIVERS OF TOXICITY FOR SMALL MOLECULES: EVALUATING PLASMA-TISSUE CONCENTRATION RELATIONSHIPS. D. Diaz. Investigative Safety Assessment, Genentech, South San Francisco, CA. #857 4:13 MAPPING ADVERSE DRUG REACTIONS IN CHEMICAL SPACE. J. Scheiber. Pharmacology Research & Early Development Informatics, Disease & Translational Informatics, Pharmacology Research and Early Development (pRED), Penzberg, Germany. Sponsor: D. Hartley. 188 Education-Career Development Sessions Exhibitor Hosted Sessions Featured Sessions Historical Highlights Informational Sessions Platform Sessions
Society of Toxicology 2011 Program Description (Continued) Abstract # Monday Afternoon, March 7 2:00 PM to 4:45 PM Room 202B Platform Session: Advancing Assessment Approaches: Pesticides and Other Key Contaminants Chairperson(s): Jeanelle Martinez, U.S. EPA, Cincinnati, OH, and Paul Price, The Dow Chemical Company, Midland, MI. #858 2:00 INNOVATIONS IN TOXICITY TESTING – AN INTEGRATED APPROACH TO TESTING OF A NEW AGROCHEMICAL BASED ON SOUND SCIENCE AND THE “3RS” PRINCIPLES ON ANIMAL RESEARCH. C. Terry 1 , R. J. Rasoulpour 2 , B. Gollapudi 2 and R. Billington 1 . 1 Dow AgroSciences LLC, Oxfordshire, United Kingdom and 2 The Dow Chemical Company, Midland, MI. #859 2:19 CROSS-SPECIES GENE EXPRESSION CHANGES IN PRIMARY HEPATOCYTES EXPOSED TO 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN. J. Rowlands 1 , R. A. Budinsky 1 , A. A. Dombkowski 2 and R. S. Thomas 3 . 1 Toxicology and Environmental Research & Consulting, The Dow Chemical Company, Midland, MI, 2 Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI and 3 Center for Genomic Biology and Bioinformatics, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. #860 2:38 COMPARATIVE QSAR STUDIES OF MONO- HYDROXYLATED POLYCHLORINATED BIPHENYLS AND THEIR POTENTIAL ESTROGENIC EFFECTS. P. Ruiz, O. Faroon, B. Fowler and M. Mumtaz. Department of Toxicology and Environmental Medicine, ATSDR, Atlanta, GA. #861 2:57 MOLECULAR FIELD TOPOLOGY ANALYSIS OF STRUCTURAL DETERMINANTS FOR ACUTE AND DELAYED NEUROTOXICITY OF O-PHOSPHORYLATED OXIMES. G. F. Makhaeva 1 , E. V. Radchenko 2 , V. B. Sokolov 1 , V. A. Palyulin 2 , N. S. Zefirov 1,2 and R. J. Richardson 3 . 1 Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russian Federation, 2 Chemistry Department, M.V. Lomonosov Moscow State University, Moscow, Russian Federation and 3 Toxicology Program, Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI. #862 3:15 FRAMEWORK FOR INTEGRATION OF HUMAN AND ANIMAL DATA FOR RISK ASSESSMENT PURPOSES: CHLORPYRIFOS NEUROBEHAVIORAL DATA AS CASE- STUDY. A. A. Li 1 , K. Lowe 1 , L. McIntosh 1 and P. Mink 2 . 1 Health Sciences, Exponent Inc., San Francisco, CA and 2 Epidemiology, Emory University, Atlanta, GA. #863 3:33 DEVELOPMENT OF SURFACE CLEAN UP LEVELS FOR ACUTE AND CHRONIC EXPOSURE TO TARGET CHEMICALS. J. M. Martinez 1 , S. A. Hines 2 and D. J. Chappie 2 . 1 Office of Emergency Management, U.S. EPA, Cincinnati, OH and 2 Battelle, Cincinnati, OH. Abstract # #864 3:51 USING PBPK/PD MODELS TO INCORPORATE CHEMICAL AND NON-CHEMICAL STRESSORS INTO CUMULATIVE RISK ASSESSMENT: A CASE STUDY OF PESTICIDE EXPOSURES. S. C. Wason 1,2 , T. J. Smith 1 , M. J. Perry 1 and J. I. Levy 1 . 1 Environmental Health, Harvard School of Public Health, Boston, MA and 2 Gradient, Cambridge, MA. Sponsor: A. Lewis. #865 4:09 ASSESSMENT OF AGGREGATE PERINATAL EXPOSURE TO BPA. D. A. Sarigiannis 1,2 and S. Karakitsios 1 . 1 Institute for Health and Consumer Protection, European Commission - Joint Research Centre, Ispra, Varese, Italy and 2 Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece. Sponsor: L. Birnbaum. #866 4:27 USE OF A PBPK/PD MODEL TO DERIVE AGE-SPECIFIC INTERSPECIES (UF A ) AND INTERINDIVIDUAL (UF H ) UNCERTAINTY FACTORS FOR CHLORPYRIFOS. P. S. Price 1 , P. M. Hinderliter 2 and T. S. Poet 2 . 1 Toxicology & Environmental Research & Consulting, The Dow Chemical Company, Midland, MI and 2 Battelle Pacific Northwest Division, Richland, WA. Monday Afternoon, March 7 2:00 PM to 4:45 PM Room 201 Platform Session: Alternative Methods in Developmental Neurotoxicology: Validation and Application Chairperson(s): Abby Li, Exponent Health Sciences, San Francisco, CA, and Merle Paule, U.S. FDA, Jefferson, AR. #867 2:00 ASSESSMENT OF 16 CHEMICALS ON PROLIFERATION AND APOPTOSIS IN HUMAN NEUROPROGENITOR CELLS USING HIGH-CONTENT IMAGE ANALYSIS (HCA). M. E. Culbreth, J. A. Harrill, T. M. Freudenrich, W. R. Mundy and T. J. Shafer. Integrated Systems Toxicology, U.S. EPA, Research Triangle Park, NC. #868 2:24 TOXIC ALTERATIONS OF DOPAMINERGIC NEURON DEVELOPMENT FROM PLURIPOTENT STEM CELLS AFTER CHRONIC LOW-DOSE EXPOSURE TO METALS DURING THE LATE MATURATION PHASE. M. Leist, S. Schildknecht, S. Kadereit and B. Zimmer. In Vitro Toxicology and Biomedicine, University Konstanz, Konstanz, Germany. #869 2:48 IS THE PENTABDE REPLACEMENT, TRIS (1, 3-DICHLORO-2-PROPYL) PHOSPHATE (TDCPP), A DEVELOPMENTAL NEUROTOXICANT? STUDIES IN PC12 CELLS. L. Dishaw 1 , C. M. Powers 2 , I. T. Ryde 1 , S. C. Roberts 1 , F. J. Seidler 2 , T. A. Slotkin 2 and H. M. Stapleton 1 . 1 Nicholas School of the Environment, Duke University, Durham, NC and 2 Pharmacology and Cancer Biology, Duke University, Durham, NC. #870 3:12 MULTIPARAMETRIC LIVE CELL IMAGING OF IMPAIRED NEURITE OUTGROWTH IN HIGH-DENSITY CULTURES OF HUMAN NEURONAL PRECURSORS. M. Daneshian, N. Stiegler, F. Matt and M. Leist. In Vitro Toxicology and Biomedicine, University Konstanz, Konstanz, Germany. MONday Poster Sessions Regional Interest Session Roundtable Sessions Symposium Sessions Thematic Sessions Workshop Sessions 189
Page 1 and 2:
50 th Anniversary Annual Meeting &
Page 3 and 4:
Scientific Program Overview A page
Page 5 and 6:
9:00 AM-12:30 PM POSTER SESSionS
Page 7 and 8:
March 6-10, 2011 Walter E. Washingt
Page 9 and 10:
Celebration Activities Historical H
Page 11 and 12:
of the Society Regional Chapter Yea
Page 13 and 14:
SOT Presidents 1961-2011 1966 1967
Page 15 and 16:
The SOT Council Thanks and Recogniz
Page 17 and 18:
of the Past 50 Years 2003 Michael D
Page 19 and 20:
Thank You to the following individu
Page 21 and 22:
SOT Celebration Event Floor Plan Ba
Page 23 and 24:
50 th Anniversary Annual Meeting an
Page 25 and 26:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 27 and 28:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 29 and 30:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 31 and 32:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 33 and 34:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 35 and 36:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 37 and 38:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 39 and 40:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 41 and 42:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 43 and 44:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 45 and 46:
Toxicological Sciences The Official
Page 47 and 48:
Society of Toxicology 2011 Walter E
Page 49 and 50:
Society of Toxicology 2011 Washingt
Page 51 and 52:
Society of Toxicology 2011 Map of W
Page 53 and 54:
2011 SOT 50 th Anniversary Featured
Page 55 and 56:
Society of Toxicology 2011 Washingt
Page 57 and 58:
Society of Toxicology 2011 ToxExpo
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Society of Toxicology 2011 Exhibito
Page 65 and 66:
Creating a Safer and Healthier Worl
Page 67 and 68:
Society of Toxicology 2011 General
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
SOT Job Bank YOUR RECRUITMENT AND E
Page 83 and 84:
Society of Toxicology 2011 Career R
Page 85 and 86:
Society of Toxicology 2011 SOT 2011
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Society of Toxicology 2011 2011 Awa
Page 95 and 96:
Endowment Awardees for SOT’s 50 t
Page 97 and 98:
Society of Toxicology 2011 SOT Endo
Page 99 and 100:
Society of Toxicology 2011 Recognit
Page 101 and 102:
Society of Toxicology 2011 Recognit
Page 103 and 104:
Society of Toxicology 2011 RC, SIG,
Page 105 and 106:
Society of Toxicology 2011 Student
Page 107 and 108:
Society of Toxicology 2011 Outreach
Page 109 and 110:
Society of Toxicology 2011 Satellit
Page 111 and 112:
Society of Toxicology 2011 Continui
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Society of Toxicology 2011 Scientif
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Society of Toxicology 2011 Poster S
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Society of Toxicology 2011 Program
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160: Society of Toxicology 2011 Program
Page 209: Society of Toxicology 2011 Program
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Society of Toxicology 2011 Author I
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Society of Toxicology 2011 Abstract
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Society of Toxicology 2011 2010-201
Page 427 and 428:
Society of Toxicology 2011 Elected
Page 429 and 430:
Society of Toxicology 2011 Elected
Page 431 and 432:
Society of Toxicology 2011 Regional
Page 433 and 434:
Society of Toxicology 2011 Specialt
Page 435 and 436:
Society of Toxicology 2011 Specialt
Page 437 and 438:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 439 and 440:
Society of Toxicology 2011 Endowmen
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Society of Toxicology 2011 SOT Affi
Page 449 and 450:
Society of Toxicology 2011 Notes up
Page 451 and 452:
Society of Toxicology 2011 Notes up
Page 453 and 454:
Society of Toxicology 2011 Headquar
Page 455 and 456:
QUICK REFERENCE Visit www.mwata.com
show all

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?